Participant flow

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer · Source last updated 2021-04-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   XL184 175 mg L-malate salt weight; 138 mg freebase equivalent weight, oral capsules once daily

   id

   FG000

   title

   XL184 (Cabozantinib)

2. description

   oral capsules once daily

   id

   FG001

   title

   Placebo

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         35

      2. group Id

         FG001

         num Subjects

         9

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         5

      type

      Death

   3. reasons

      1. group Id

         FG000

         num Subjects

         2

      2. group Id

         FG001

         num Subjects

         0

      type

      Physician Decision

   4. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         2

      type

      Did not receive drug

   5. reasons

      1. group Id

         FG000

         num Subjects

         58

      2. group Id

         FG001

         num Subjects

         67

      type

      Disease progression per PI

   6. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      data unavailable

   7. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         13

      type

      Withdrawal by Subject

   milestones

   1. achievements

      1. comment

         Randomized

         group Id

         FG000

         num Subjects

         219

      2. comment

         Randomized

         group Id

         FG001

         num Subjects

         111

      type

      STARTED

   2. achievements

      1. comment

         Continuing treatment at data cutoff for primary analysis, but subsequently discontinued study

         group Id

         FG000

         num Subjects

         98

      2. comment

         Continuing study treatment at the time of data cut-off.

         group Id

         FG001

         num Subjects

         15

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         121

      2. group Id

         FG001

         num Subjects

         96

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

First patient enrolled 10 September 2008, last patient enrolled 27 February 2011. Data cut off date 15 June 2011.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice